Table 3

Baseline immunological characteristics of 5 clusters of 79 PHID patients, ALTADIH Cohort, 2007-2010
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
n = 33 n = 18 n = 4 n = 8 n = 16
IgG g/L 4.37 (3.80, 5.32) 5.73 (4.7, 6.3) 4.68 (2.69, 5.29) 1.44 (0.30, 2.71) 3.69 (1.65, 4.22)
IgA g/L 0.63 (0.14, 1.62) 1.02 (0.07, 1.55) 0.60 (0.04, 2.09) 0.15 (0.01, 0.43) 0.19 (0.05, 0.79)
IgM g/L 0.55 (0.31, 1.09) 0.48 (0.24, 0.78) 0.54 (0.34, 0.62) 0.16 (0.05, 0.42) 0.27 (0.20, 0.47)
B cells
CD19+ cells/mm3 157 (128, 244) 128 (102, 211) 49 (20, 87) 122 (94, 176) 51 (29, 119)
CD27-IgD+ % CD19+ 68.85 (52.03, 74.47) 68.89 (57.94, 77.24) 49.52 (10.73, 80.43) 90.89 (82.94, 93.31) 84.03 (70.93, 90.82)
CD27-IgD- % CD19+ 2.80 (2.18, 4.38) 3.90 (2.24, 6.42) 6.13 (2.64, 23.40) 2.40 (1.67, 2.58) 2.65 (1.72, 4.22)
CD27 + IgD+ % CD19+ 15.01 (10.11, 23.19) 10.53 (4.42, 13.73) 5.67 (2.43, 8.57) 3.57 (2.21, 7.20) 4.92 (1.32, 7.92)
CD27 + IgD- % CD19+ 14.39 (7.08, 20.05) 13.93 (7.26, 24.33) 7.77 (2.43, 19.38) 2.55 (0.94, 3.91) 2.97 (0.36, 6.66)
T cells
CD3+ cells/mm3 1363 (1076, 1787) 1045 (883, 1456) 2756 (1472, 4183) 831 (658, 1075) 579 (407, 837)
CD4+ cells/mm3 835 (571, 1214) 789 (573, 967) 848 (609, 1227) 382 (302, 565) 308 (244, 565)
CD8+ cells/mm3 477 (358, 604) 270 (159, 383) 1621 (710, 2682) 293 (196, 362) 213 (141, 266)
CD4+/CD8+ ratio 1.89 (1.45, 2.42) 2.77 (2.31, 4.08) 0.60 (0.42, 1.06) 1.26 (0.67, 2.65) 1.89 (1.17, 2.61)
CD8+ T cells
CD45RA + CCR7+ % CD8+ 19.05 (11.11, 34.59) 28.47 (13.32, 43.67) 1.52 (0.56, 2.75) 4.91 (1.53, 53.19) 35.56 (10.29, 53.19)
CD45RA-CCR7+ % CD8+ 0.83 (0.46, 1.90) 4.60 (1.96, 7.97) 0.53 (0.21, 0.82) 0.82 (0.30, 1.20) 1.37 (0.85, 1.96)
CD45RA-CCR7- % CD8+ 31.28 (24.26, 36.96) 43.13 (32.60, 57.14) 36.82 (16.56, 57.25) 39.24 (30.69, 59.20) 29.14 (17.47, 42.55)
CD45RA + CCR7- % CD8+ 41.48 (32.61, 52.32) 22.30 (16.87, 27.10) 40.75 (13.96, 59.90) 48.28 (30.47, 63.41) 29.25 (18.76, 39.37)
CD8 + CD57+ % CD8+ 17.52 (9.42, 30.97) 7.38 (4.41, 15.97) 27.36 (19.36, 47.30) 39.61 (33.78, 51.16) 13.51 (8.35, 23.44)
Activated T cells
CD3 + HLA-DR+ % CD3+ 12.04 (7.62, 16.95) 9.87 (7.11, 12.83) 52.00 (32.71, 59.56) 46.56 (40.76, 57.25) 13.65 (6.19, 20.33)
CD4 + HLA-DR+ % CD4+ 5.88 (4.94, 9.17) 6.75 (4.95, 9.13) 48.30 (26.32, 56.25) 43.87 (30.88, 49.95) 11.54 (6.52, 18.33)
CD8 + HLA-DR+ % CD8+ 25.48 (14.86, 31.93) 19.73 (14.18, 26.44) 53.48 (37.05, 65.52) 62.14 (47.01, 76.39) 15.12 (10.65, 28.64)
Regulatory T cells cells/mm3 54 (33, 76) 41 (24, 82) 18 (13, 22) 19 (12, 24) 15 (8, 18)
NK cells cells/mm3 143 (100, 214) 174 (121, 230) 268 (146, 388) 75 (55, 103) 41 (26, 70)
Dendritic cells
Myeloid /ml 11940 (8751, 17805) 11422 (6616, 13457) 9122 (5662, 29989) 7795 (4086, 10548) 5420 (4107, 9683)
Plasmacytoid /ml 7217 (4801, 11084) 6152 (3599, 9836) 2771 (1766, 8490) 3073 (1351, 3618) 2766 (2194, 4255)
Gammadelta cells cells/mm3 44 (20, 74) 27 (11, 54) 396 (178, 579) 19 (6, 92) 16 (9, 26)
Gammadelta 2 % GD 62.96 (40.85, 73.68) 78.71 (75.00, 89.39) 13.40 (8.77, 30.62) 6.59 (4.09, 25.61) 25.00 (12.41, 55.96)

Results are expressed as medians (interquartile range values).

Picat et al.

Picat et al. BMC Immunology 2014 15:13   doi:10.1186/1471-2172-15-13

Open Data